了解和处理慢性淋巴细胞白血病的感染并发症。

IF 2.7 3区医学 Q2 HEMATOLOGY

Hematology-Oncology Clinics of North America Pub Date : 2025-07-25 DOI:10.1016/j.hoc.2025.05.003

Noomi Vainer, Andreas Katsimigas, Emelie Curovic Rotbain, Carsten Utoft Niemann

{"title":"了解和处理慢性淋巴细胞白血病的感染并发症。","authors":"Noomi Vainer, Andreas Katsimigas, Emelie Curovic Rotbain, Carsten Utoft Niemann","doi":"10.1016/j.hoc.2025.05.003","DOIUrl":null,"url":null,"abstract":"Despite major improvements in the treatment landscape of chronic lymphocytic leukemia (CLL), infections remain the major cause of death for patients with CLL. Management of infections in patients with CLL includes antimicrobial therapy, prophylactic vaccinations, and immunoglobulin replacement. Prognostic tools to identify patients with CLL at high risk of infections are warranted. Comorbidities, history of infections, and patient preferences should be considered in addition to molecular prognostic markers when choosing treatment strategy for patients with CLL. Targeted, sequential doublet therapy may provide similar efficacy with less immunosuppression as compared to triplet targeted therapy and indefinite monotherapy.","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia.\",\"authors\":\"Noomi Vainer, Andreas Katsimigas, Emelie Curovic Rotbain, Carsten Utoft Niemann\",\"doi\":\"10.1016/j.hoc.2025.05.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite major improvements in the treatment landscape of chronic lymphocytic leukemia (CLL), infections remain the major cause of death for patients with CLL. Management of infections in patients with CLL includes antimicrobial therapy, prophylactic vaccinations, and immunoglobulin replacement. Prognostic tools to identify patients with CLL at high risk of infections are warranted. Comorbidities, history of infections, and patient preferences should be considered in addition to molecular prognostic markers when choosing treatment strategy for patients with CLL. Targeted, sequential doublet therapy may provide similar efficacy with less immunosuppression as compared to triplet targeted therapy and indefinite monotherapy.\",\"PeriodicalId\":55060,\"journal\":{\"name\":\"Hematology-Oncology Clinics of North America\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology-Oncology Clinics of North America\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.hoc.2025.05.003\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology-Oncology Clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hoc.2025.05.003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

尽管慢性淋巴细胞白血病（CLL）的治疗领域取得了重大进展，但感染仍然是CLL患者死亡的主要原因。CLL患者感染的管理包括抗菌素治疗、预防性疫苗接种和免疫球蛋白替代。有必要使用预后工具来识别具有高风险感染的CLL患者。在为CLL患者选择治疗策略时，除了分子预后标志物外，还应考虑合并症、感染史和患者偏好。与三联靶向治疗和无限期单药治疗相比，靶向序贯双联治疗可能提供相似的疗效，但免疫抑制较小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia.

Despite major improvements in the treatment landscape of chronic lymphocytic leukemia (CLL), infections remain the major cause of death for patients with CLL. Management of infections in patients with CLL includes antimicrobial therapy, prophylactic vaccinations, and immunoglobulin replacement. Prognostic tools to identify patients with CLL at high risk of infections are warranted. Comorbidities, history of infections, and patient preferences should be considered in addition to molecular prognostic markers when choosing treatment strategy for patients with CLL. Targeted, sequential doublet therapy may provide similar efficacy with less immunosuppression as compared to triplet targeted therapy and indefinite monotherapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematology-Oncology Clinics of North America 医学-血液学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.